Continuing a vein of discussion posted previously, Trickle Down Technologies in Medtech, it is worth looking at the advanced wound management products represented by hemostats (i.e., hemostatic agents, like ZMedica's QuikClot), fibrin and other sealants, high-strength medical adhesives and products for prevention of post-surgical adhesion and look at their relative size in a set of well-developed economies like that of the Americas versus the same for emerging markets, such as represented by Asia/Pacific excluding Japan and Korea.
The point of this comparison is to illustrate that markets for advanced technologies grow first and fastest in advanced economies. In the case of advanced wound management products, least "advanced" product is hemostats, while the most advanced is high-strength medical adhesives (even moreso than anti-adhesion products). See below in graphics comparing in absolute terms the market segmentation (stacked column chart) and the relative size of segments (two pie charts) for the Americas and Emerging Asia/Pacific.
Source: MedMarket Diligence Report #S190.
Hemostats represent a relatively low hurdle to market entry, since the important functions of the product are simply to stop bleeding without being toxic. On the other end of the spectrum is high-strength medical adhesives, which must create strong tissue adhesion without toxicity and, as has been demonstrated by toxic cyanoacrylates, this is indeed a challenge.
Having said this, despite the technical challenge, which exists independently of geographic market differences, the real challenge (beyond gaining U.S. or EU regulatory approval) is bringing the price of these advanced products down to levels can accelerate their more rapid introduction into growth markets like the emerging Asia/Pacific (see CHINA).